CardioMEMS HF System

 

The CardioMEMS™ HF System

CardioMEMS™ HF System

St. Jude Medical is proud to introduce a new tool for comprehensive heart failure care. The CardioMEMS™ HF System is the first and only FDA-approved heart failure (HF) monitor proven to significantly reduce HF hospital admissions and improve quality of life in NYHA class III patients.1

When used by clinicians to manage HF, the CardioMEMS HF System is:

  • Safe and reliable – 98.6% of patients were free from device or system complications2
  • Clinically proven – reduced HF admissions by 37%2
  • Proactive and personalized – patient management through direct monitoring of PA pressure and titration of medications

Learn more about the CardioMEMS HF System >>>

Learn More about the CardioMEMS HF System for patients >>>

The Latest Data

New Data:

Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalizations and All-Cause 30-Day Readmissions in Medicare-Eligible Patients With NYHA Class III Heart Failure: Results From the CHAMPION Trial

read the clinical data

On Demand Webinars: 

Discover the CardioMEMS™ HF System – A Game Changer For HF Patient Management

watch now

News:

Data Shows the CardioMEMS HF System Significantly Reduced 30-day Hospital Readmission Rates

Read the news release

 
 

About St. Jude Medical

St. Jude Medical is a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive, epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical focus areas that include cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. 



About St. Jude Medical >>>

 
 

References

1. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. Lancet. 2011;377(9766):658-66.
2. Adamson et al., Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalizations and 30-Day Readmissions in Medicare-Eligible Patients with NYHA Class III Heart Failure: Results from the CHAMPION Trial AHA 2014, Chicago. Abstract 16744.

Indications, Safety & Warnings